

FORM PTO 1390  
(REV 5-93)

US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NUMBER  
2006\_1150ATRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. §371U.S. APPLICATION NO.  
107586499  
NEWInternational Application No.  
PCT/JP2005/000786International Filing Date  
January 21, 2005Priority Date Claimed  
January 23, 2004**Title of Invention**

EPIDERMAL GROWTH FACTOR RECEPTOR-DERIVED PEPTIDES

Applicant(s) For DO/EO/US  
Kyogo ITOH et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. §371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☒ A translation of the International Application into English (35 U.S.C. §371(c)(2)). **ATTACHMENT A**
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)).
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19.
9. ☒ An **executed** oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)). **ATTACHMENT B**
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).

**Items 11. to 14. below concern other document(s) or information included:**

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.

**ATTACHMENT C**

13. ☒ A FIRST preliminary amendment. **ATTACHMENT D**  
☐ A SECOND or SUBSEQUENT preliminary amendment.

14. ☒ Other items or information: **Form PCT/IB/304 - ATTACHMENT E**

**WO 2005/071075 - ATTACHMENT F****International Search Report - ATTACHMENT G**

**Sequence Listing in paper and computer readable form are  
identical and contain no new matter**

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEE FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 28-0975.

U.S. APPLICATION NO. <b>10/586499</b> NEW		INTERNATIONAL APPLICATION NO. PCT/JP2005/000786		ATTORNEY'S DOCKET NO. 2006_1150A							
15. [X] The following fees are submitted  Basic National Stage Fee ..... \$300.00 National Stage Search Fee (International Search Report provided - 37 CFR 1.492(b)(2)) ..... \$400.00 National Stage Examination Fee ..... \$200.00 Specification/drawings in excess of 100 pages ( units of 50 x \$250.00) = ..... \$				<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:50%;">CALCULATIONS</th> <th style="width:50%;">PTO USE ONLY</th> </tr> <tr> <td colspan="2" style="height: 40px;"></td> </tr> <tr> <td>\$900.00</td> <td></td> </tr> </table>		CALCULATIONS	PTO USE ONLY			\$900.00	
CALCULATIONS	PTO USE ONLY										
\$900.00											
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$900.00							
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$							
Claims	Number Filed	Number Extra	Rate								
Total Claims	36 - 20 =	16	X \$50.00	\$800.00							
Independent Claims	1 - 3 =	0	X \$200.00	\$							
Multiple dependent claim(s) (if applicable)			+ \$360.00	\$360.00							
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$2,060.00							
<input type="checkbox"/> Small Entity Status is hereby asserted. Above fees are reduced by 1/2.				\$							
<b>SUBTOTAL =</b>				\$2,060.00							
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+ \$							
<b>TOTAL NATIONAL FEE =</b>				\$2,060.00							
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +				\$40.00							
<b>TOTAL FEES ENCLOSED =</b>				\$2,100.00							
				Amount to be refunded	\$						
				Amount to be charged	\$						
a. [X] A check in the amount of <u>\$2,100.00</u> to cover the above fees is enclosed. A duplicate copy of this form is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 23-0975 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>23-0975</u> .											
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>											
19. CORRESPONDENCE ADDRESS          <div style="text-align: center;">           CUSTOMER NO.  <b>000513</b> </div>				By: <u>Warren M. Cheek, Jr.</u> Warren M. Cheek, Jr., Registration No. 33,367  WENDEROTH, LIND & PONACK, L.L.P. 2033 "K" Street, N.W., Suite 800 Washington, D.C. 20006-1021 Phone: (202) 721-8200 Fax: (202) 721-8250  July 20, 2006							

 [CHECK NO. 75213]  
 [2006\_1150A]

10/586499

IAP11 Rec'd PCT/PTO 20 JUL 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Kyogo ITOH et al. : **Mail Stop: PCT**  
Serial No. NEW : Attorney Docket No. 2006\_1150A  
Filed July 20, 2006 :

EPIDERMAL GROWTH FACTOR  
RECEPTOR-DERIVED PEPTIDES  
[Corresponding to PCT/JP2005/000786  
Filed January 21, 2005]

---

**SUBMISSION OF ENGLISH/JAPANESE**

**DECLARATION AND POWER OF ATTORNEY**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The attached Declaration and Power of Attorney includes both Japanese language text and English language text. The English language text constitutes an accurate translation of the Japanese language text.

Respectfully submitted,

Kyogo ITOH et al.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
July 20, 2006